FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology and molecular biology. Disclosed is an antisense oligomer for treating muscular dystrophy selected from a group: an antisense oligomer comprising a nucleotide sequence SEQ ID NO: 1 or 2; and an antisense oligomer which consists of a nucleotide sequence comprising a deletion, substitution, insertion and/or addition of 1–5 nucleotides in the nucleotide sequence SEQ ID NO: 1 or 2, and having activity causing skipping exon 51 in human dystrophin gene.
EFFECT: invention can be used in medicine for controlling muscular dystrophy.
21 cl, 8 tbl, 1 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2730681C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2695430C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2825834C2 |
| ANTISENSE NUCLEIC ACIDS | 2011 |
|
RU2567664C2 |
| ANTISENSE NUCLEIC ACID | 2016 |
|
RU2724554C2 |
| COMPOSITION CONTAINING ANTISENSE OLIGONUCLEOTIDE AND ITS USE FOR THE TREATMENT OF DUSCHENNE MUSCULAR DYSTROPHY | 2019 |
|
RU2799442C2 |
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2619184C2 |
| ANTISENSE NUCLEIC ACIDS | 2018 |
|
RU2681470C1 |
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2651468C1 |
| OLIGONUCLEOTIDE FOR TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | 2013 |
|
RU2674600C2 |
